Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) CEO Ludwig Hantson sold 2,553 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total value of $310,521.39. Following the completion of the transaction, the chief executive officer now directly owns 36,172 shares in the company, valued at $4,399,600.36. The transaction was disclosed in a filing with the SEC, which is available at this link.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down $2.26 during midday trading on Friday, hitting $122.69. The stock had a trading volume of 2,094,900 shares, compared to its average volume of 2,318,100. The company has a market cap of $27,400.00, a PE ratio of 54.77, a price-to-earnings-growth ratio of 1.05 and a beta of 1.17. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.32 by $0.12. The firm had revenue of $859.00 million for the quarter, compared to analysts’ expectations of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The company’s revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.23 EPS. analysts expect that Alexion Pharmaceuticals, Inc. will post 4.82 EPS for the current fiscal year.
Several equities analysts recently issued reports on the company. Raymond James Financial reaffirmed an “outperform” rating and issued a $130.00 price objective (down from $178.00) on shares of Alexion Pharmaceuticals in a research report on Thursday. They noted that the move was a valuation call. UBS Group cut Alexion Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research report on Thursday. BidaskClub raised Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 27th. Robert W. Baird raised Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $150.00 price objective on the stock in a research report on Monday, December 18th. Finally, Credit Suisse Group reaffirmed a “buy” rating and issued a $166.00 price objective on shares of Alexion Pharmaceuticals in a research report on Tuesday, December 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty have issued a buy rating to the stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $153.61.
COPYRIGHT VIOLATION NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) CEO Ludwig Hantson Sells 2,553 Shares” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://sportsperspectives.com/2018/01/05/alexion-pharmaceuticals-inc-alxn-ceo-ludwig-hantson-sells-2553-shares.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.